Leerink Partners Initiates Tekmira Pharmaceuticals At Outperform

Analysts at Leerink Partners initiated coverage on Tekmira Pharmaceuticals TKMR with a Outperform rating. The target price for Tekmira Pharmaceuticals is set to $25. Tekmira Pharmaceuticals' shares gained 6.08% to $19.18 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: InitiationAnalyst RatingsLeerink Partners
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!